sacituzumab
gilead
['sacituzumab', 'bcsm', 'breast', 'sacitu, govi']
. discusses the approval of sacituzumab govitecan, and it's clinical impact on patients with hormone receptor positive or her2-negative or -low metastatic breast cancer who are endocrine therapy refractory. #bcsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.